MANILA, Philippines — The Food and Drug Administration (FDA) has issued a stern warning to food manufacturers, asserting that the absence of specific regulatory safety limits is not a “shield against accountability.”
The agency’s statement comes in response to recent public comments from Nestlé Philippines regarding the voluntary recall of its Nan Optipro and Nankid Optipro infant formula products. Nestlé had pointed out that there are currently no established food safety or regulatory limits for the specific substance involved in the recall.
The Substance in Question The recall, which began on January 9, was triggered by a quality issue involving an ingredient—arachidonic acid-rich oil—supplied by a third party. The FDA revealed that very low levels of cereulide, a toxin produced by the microorganism Bacillus cereus, were detected in the oil. Cereulide is known to cause gastrointestinal issues such as vomiting and diarrhea.
Duty of Care for Infants The FDA emphasized that for products intended for infants and young children, manufacturers must exercise the “highest degree of precaution,” even when scientific data is evolving.
“The absence of definitive scientific conclusions… does not absolve manufacturers of their duty to ensure product safety,” the FDA stated. “Our mandate is prevention, not reaction. We will not wait for conclusive outcomes before acting when the safety of infants is at stake.”
Reports of Illness As of January 15, the FDA has received 18 reports from parents and caregivers whose children experienced adverse symptoms after consuming the affected formula. Symptoms included abdominal pain and gastrointestinal distress, with some cases requiring medical attention. Nestlé has maintained that available data is inconclusive in linking the exposure directly to these health effects, but the FDA insists these reports require immediate regulatory intervention.
Nationwide Inspections In a parallel effort, FDA enforcement teams have launched a countrywide sweep to ensure the recalled batches are removed from shelves.
- Luzon: 65 Nestlé products were flagged across various establishments and have been pulled or documented for retrieval.
- Visayas & Mindanao: Most establishments have already cleared the affected stocks, with a high compliance rate reported across both regions.
The FDA warned that if the ongoing investigation establishes negligence, it will pursue the “full range of regulatory and legal actions” to safeguard public health. Consumers who have purchased these products are urged to check the batch numbers and coordinate with retailers or Nestlé for returns and refunds.